Electrocardiogram Clinical Validation Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85018
- HOPE Research Institute
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Washington Hospital Center
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55102
- Healtheast
-
-
New York
-
Manhasset, New York, United States, 11030
- Northwell Health North Shore University Hospital
-
New York, New York, United States, 10075
- Northwell Health Lenox Hill Hospital
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- MedStar Health Cardiac Electrophysiology at Fairfax
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to read, understand, and provide written informed consent;
- Willing and able to participate in the study procedures as described in the consent form;
- Individuals who are 22 years of age and older;
- Able to communicate effectively with and follow instructions from the study staff;
- Have a wrist circumference that fits within the device band; and
- For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening.
Exclusion Criteria:
- Physical disability that precludes safe and adequate testing;
- Mental impairment resulting in limited ability to cooperate;
- Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD);
- Acute myocardial infarction within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, increases the risk to the subject or renders data uninterpretable;
- Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis within 90 days of screening;
- Stroke or transient ischemic attack within 90 days of screening;
- Subjects taking rhythm control drugs;
- Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis, or allergic contact dermatitis on both wrists or over electrode attachment sites, including known allergy or sensitivity to silicone bands primarily used in wrist-worn fitness devices;
- Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or ECG electrodes;
- A history of abnormal life-threatening rhythms as determined by the Investigator;
- Significant tremor that prevents subject from being able to hold still;
- Women who are pregnant at the time of study participation; and
- Subjects enrolled into the SR population must not have any diagnosis of AF.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
OTHER: Atrial fibrillation (AF)
Patients with a known history of AF who are in AF at the time of study screening.
|
Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device.
All participants will record three simultaneous 12-lead and single-lead ECGs.
|
|
OTHER: Normal Sinus Rhythm (SR)
Patients with no known diagnosis of AF or other arrhythmia
|
Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device.
All participants will record three simultaneous 12-lead and single-lead ECGs.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Specificity of rhythm classification
Time Frame: 1 Day
|
Number of participants with a SR software rhythm classification in agreement with a physician's interpretation of heart rhythm based on gold standard 12-lead ECG
|
1 Day
|
|
Sensitivity of rhythm classification
Time Frame: 1 Day
|
Number of participants with an AF software rhythm classification in agreement with a physician's interpretation of heart rhythm based on gold standard 12-lead ECG
|
1 Day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of ECGs that pass a visual overlay
Time Frame: Day 1
|
Number of participants with software's ability to produce a clinically equivalent waveform in agreement to a gold standard Lead I reference
|
Day 1
|
|
Difference in R-wave amplitudes between the software and gold standard reference
Time Frame: Day 1
|
Number of participants with software's ability to produce a clinically equivalent waveform in agreement to a gold standard Lead I reference
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ECG-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.